Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
暂无分享,去创建一个
D. Rader | T. Ganz | D. Cines | K. Bdeir | E. Lavi | A. Higazi | D. Jamieson | W. Kane | D. Usher | A. M. Ulrich
[1] T. Ganz,et al. Defensin Modulates Tissue-type Plasminogen Activator and Plasminogen Binding to Fibrin and Endothelial Cells* , 1996, The Journal of Biological Chemistry.
[2] R. Rosenson. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. , 1996, Archives of internal medicine.
[3] H. Becher,et al. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. , 1996, Thrombosis research.
[4] E. Feskens,et al. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[5] G. Heiss,et al. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[6] B. Bouma,et al. Effect of Lipoprotein(a) and LDL on Plasminogen Binding to Extracellular Matrix and on Matrix-dependent Plasminogen Activation by Tissue Plasminogen Activator , 1996, Thrombosis and Haemostasis.
[7] S. Biro,et al. Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways , 1995, FEBS letters.
[8] D. Rader,et al. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. , 1995, The American journal of pathology.
[9] A. Stead,et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. , 1995, Stroke.
[10] M. Callow,et al. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). , 1995, The Journal of clinical investigation.
[11] P. Ridker,et al. Plasma concentration of lipoprotein(a) and the risk of future stroke. , 1995, JAMA.
[12] A. Higazi,et al. Identification of an Inhibitor of Tissue-type Plasminogen Activator-mediated Fibrinolysis in Human Neutrophils , 1995, The Journal of Biological Chemistry.
[13] D. Rader,et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. , 1995, The Journal of clinical investigation.
[14] R. Lawn,et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.
[15] D. Rader,et al. Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease , 1994, Annals of Internal Medicine.
[16] P. Harpel,et al. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. , 1994, Biochemistry.
[17] T. Ganz,et al. Defensins: a family of antimicrobial and cytotoxic peptides. , 1994, Toxicology.
[18] A. Folsom,et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1993, The American journal of medicine.
[19] A. Gown,et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[20] P. Harpel,et al. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. , 1993, Biochemistry.
[21] T. Ganz,et al. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. , 1993, The Journal of laboratory and clinical medicine.
[22] W. März,et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor‐related protein/α2‐macroglobulin receptor , 1993, FEBS letters.
[23] D. Cines,et al. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. , 1993, The Journal of biological chemistry.
[24] P. Weissberg,et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.
[25] J. Loscalzo,et al. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. , 1993, Biochemistry.
[26] M. Jauhiainen,et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus , 1993, The Lancet.
[27] H. Fukushi,et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. , 1993, The Journal of infectious diseases.
[28] R. Grimm,et al. The white blood cell count and risk for coronary heart disease. , 1992, American heart journal.
[29] D. Siscovick,et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. , 1992, JAMA.
[30] V. Tertov,et al. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. , 1992, Clinical immunology and immunopathology.
[31] R. Klein,et al. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1992, Metabolism: clinical and experimental.
[32] M. Ultsch,et al. Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. , 1992, Biochemistry.
[33] T. Ganz,et al. An enzyme immunoassay for human defensins. , 1991, Journal of immunological methods.
[34] J. Huttunen,et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.
[35] R. Kronmal,et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[36] D. Eisenberg,et al. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. , 1991, Science.
[37] A. Salamon,et al. Immunochemistry of human Lp[a]: characterization of monoclonal antibodies that cross-react strongly with plasminogen. , 1991, Journal of lipid research.
[38] E. B. Smith,et al. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. I. Relation between fibrin and immobilization of apo B-containing lipoprotein. , 1990, Atherosclerosis.
[39] E. B. Smith,et al. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). , 1990, Atherosclerosis.
[40] R. Hammer,et al. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. , 1990, The Journal of clinical investigation.
[41] S. Surrey,et al. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. , 1990, Blood.
[42] A. Vaheri,et al. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. , 1989, The EMBO journal.
[43] M. Dietel,et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.
[44] J. Breslow,et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.
[45] A. Scanu,et al. A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.
[46] M. Selsted,et al. Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. , 1989, The Journal of biological chemistry.
[47] P. Carlsson,et al. Identification of Apo B‐100 Segments Mediating the Interaction of Low Density Lipoproteins with Arterial Proteoglycans , 1988, Arteriosclerosis.
[48] E. Chen,et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.
[49] J. Dormandy,et al. Leukocytes and the risk of ischemic diseases. , 1987, JAMA.
[50] G. Daggard,et al. CORONARY ARTERY BYPASS GRAFT FAILURE—AN AUTOIMMUNE PHENOMENON? , 1986, The Lancet.
[51] J. Neaton,et al. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. , 1985, JAMA.
[52] R I Lehrer,et al. Primary structures of three human neutrophil defensins. , 1985, The Journal of clinical investigation.
[53] T. Ganz,et al. DEFENSINS: NATURAL PEPTIDE ANTIBIOTICS IN HUMAN NEUTROPHILS , 1986 .
[54] D. Cines,et al. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. , 1984, The Journal of clinical investigation.
[55] J. McDougall,et al. Viruses in the etiology of atherosclerosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Debakey,et al. CYTOMEGALOVIRUS ANTIGEN WITHIN HUMAN ARTERIAL SMOOTH MUSCLE CELLS , 1983, The Lancet.
[57] J. Richard,et al. Leukocyte count, smoking, and myocardial infarction. , 1981, The New England journal of medicine.
[58] A. Siegelaub,et al. The leukocyte count as a predictor of myocardial infarction. , 1974, The New England journal of medicine.
[59] I. Weinbren. SPONTANEOUS PERIODIC ŒDEMA: A New Syndrome , 1963 .
[60] R. Magno,et al. Coronary heart disease , 1957 .
[61] T. Ganz,et al. Neutrophil defensins: purification, characterization, and antimicrobial testing. , 1994, Methods in enzymology.
[62] T. Clarkson,et al. Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[63] R J Glynn,et al. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. , 1990, Journal of clinical epidemiology.
[64] R. Breuer,et al. Book-Review - Contact with the Stars - the Search for Extraterrestrial Life , 1982 .